Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

303.29

Mkt cap

6.3B

Volume

934K

High

303.29

P/E Ratio

-11.53

52-wk high

368.29

Low

272.72

Div yield

N/A

52-wk low

166.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) is set to release its quarterly earnings on October 31, 2024. Analysts expect an EPS of $-7.09. Investors are keen on whether the company will surpass estimates and provide favorable guidance, as these factors can significantly impact stock prices. In the past, beating EPS estimates has led to positive stock price movements.

Portfolio Pulse from Benzinga Insights

October 30, 2024 | 5:01 pm

Madrigal Pharmaceuticals will present multiple abstracts on their drug resmetirom for NASH/MASH at the AASLD Liver Meeting in November 2024.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:19 pm

Oppenheimer analyst Jay Olson maintains an Outperform rating on Madrigal Pharmaceuticals but lowers the price target from $375 to $350.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:24 pm

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $390.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 11:20 am

Madrigal Pharmaceuticals has completed enrollment for its MAESTRO-NASH OUTCOMES study, which evaluates resmetirom for treating compensated NASH cirrhosis. Positive results could lead to the first approved medication for this condition and support full approval for noncirrhotic NASH.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:08 pm

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL).

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:08 pm

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NASH trial of Rezdiffra, showing significant improvements in health-related quality of life for NASH patients. Rezdiffra, the first FDA-approved NASH treatment, demonstrated efficacy in improving fibrosis and NASH resolution.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 12:03 pm

Citigroup analyst David Lebovitz maintains a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) but lowers the price target from $382 to $371.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 7:21 pm

Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) but lowers the price target from $405 to $360.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 1:09 pm

Madrigal Pharmaceuticals shares are trading lower following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 2:22 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.